Nanobiotix S.A.
NBTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeNanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. At a $1.50B market cap, Nanobiotix S.A. ranks as a small-cap company within healthcare. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer.
Market Cap
$1.50B
Beta
0.59
P/E (TTM)
—
P/E (Fwd)
-175.05
EPS (TTM)
$-1.27
EPS (Fwd)
$-0.17
ROE
—
ROA
-21.3%
Cash
$110.9M
Total Debt
$106.6M
Free CF
-$32.8M
52W Change
52.9%
Annual Financials
Cash vs Debt
Where NBTX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, NBTX finished 41.61% below its 150-day moving average ($36.10) and 36.92% below its 200-day moving average ($33.42). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NBTX overbought or oversold?
At the October 20, 2026 close, NBTX's RSI(14) was 13.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $110.9M in cash comfortably exceeding the $106.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$32.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet.
With a beta below 0.7, Nanobiotix S.A. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Nanobiotix S.A.'s trajectory.